166. Erythromelalgia

  1. Alan D. Irvine MD, FRCPI, FRCP2,3,
  2. Peter H. Hoeger MD4,5 and
  3. Albert C. Yan MD, FAAP, FAAD6,7
  1. Justin Daniels

Published Online: 24 MAY 2011

DOI: 10.1002/9781444345384.ch166

Harper's Textbook of Pediatric Dermatology, Volume 1, 2, Third Edition

Harper's Textbook of Pediatric Dermatology, Volume 1, 2, Third Edition

How to Cite

Daniels, J. (2011) Erythromelalgia, in Harper's Textbook of Pediatric Dermatology, Volume 1, 2, Third Edition (eds A. D. Irvine, P. H. Hoeger and A. C. Yan), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444345384.ch166

Editor Information

  1. 2

    Trinity College, Dublin, Ireland

  2. 3

    Our Lady's Children's Hospital, Dublin, Ireland

  3. 4

    University of Hamburg, Hamburg, Germany

  4. 5

    Catholic Children's Hospital Wilhelmstift, Hamburg, Germany

  5. 6

    University of Pennsylvania School of Medicine, Philadelphia, PA, USA

  6. 7

    The Children's Hospital of Philadelphia, Philadelphia, PA, USA

Author Information

  1. Pediatric Department, North Middlesex University Hospital, London, UK

Publication History

  1. Published Online: 24 MAY 2011
  2. Published Print: 3 JUN 2011

ISBN Information

Print ISBN: 9781405176958

Online ISBN: 9781444345384

SEARCH

Keywords:

  • chronic pain;
  • erythema;
  • erythermalgia;
  • erythromelalgia;
  • mis-sense mutation;
  • sodium channel

Summary

Erythromelalgia is an autosomal dominant condition in which a mis-sense mutation of the SCN9A gene affects the sodium channel Nav1.7. This results in bilateral erythematous painful hands and/or feet. Treatment is complex and the prognosis historically has been poor. A number of new treatment modalities are now available and as understanding of the molecular basis increases, these may improve.